Has Raymond Grenfell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,596 in general payments to Raymond Grenfell, MD across 886 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raymond Grenfell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raymond Grenfell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raymond Grenfell, MD

Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1780899922

Payments from drug & device makers

$15,596in general payments, 2019–2025

Across 886 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$2K
Abbott$1K
Amgen$1K
Novo Nordisk$971
Dexcom, Inc.$965
Corcept Therapeutics$841
plus $8K from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	141	$2,021
Abbott	75	$1,268
Amgen(2 entities)	73	$1,264
Novo Nordisk	41	$971
Dexcom, Inc.	54	$965
Corcept Therapeutics	42	$841
Bayer	40	$777
AstraZeneca(2 entities)	49	$738
Insulet Corporation	34	$727
Boehringer Ingelheim	40	$646
Merck	41	$644
Sanofi-aventis U.S. LLC	26	$477
Recordati_rare_diseases_inc.	13	$399
Novartis	23	$357
Esperion Therapeutics, Inc.	17	$315
Xeris Pharmaceuticals, Inc.	13	$300
Tandem Diabetes Care, Inc.	16	$244
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	13	$242
AbbVie	13	$220
Medtronic(2 entities)	10	$198
Amneal Pharmaceuticals LLC	10	$174
BETA Bionics, Inc.	10	$164
Pfizer	10	$153
GRT US Holding, Inc.	4	$136
Lifescan, Inc.	9	$130
Ascendis Pharma Endocrinology Inc	7	$120
Kyowa Kirin, Inc.	6	$111
Sequel Med Tech, LLC	5	$97
IBSA Pharma Inc.	6	$93
Amryt Pharma Holdings Ltd	3	$76
Antares Pharma, Inc.	3	$61
Neurocrine Biosciences, Inc.	3	$61
EUSA Pharma (US) LLC	2	$45
Johnson & Johnson	3	$39
Arbor Pharmaceuticals, Inc.	2	$36
Astellas Pharma US Inc	2	$35
Acella Pharmaceuticals, LLC	2	$31
Cequr Corporation	2	$31
Averitas Pharma Inc.	1	$29
Takeda Pharmaceuticals U.S.A., Inc.	2	$29
Shire North American Group Inc	2	$28
Ascensia Diabetes Care US Inc.	2	$28
Halozyme Inc	1	$25
Nalpropion Pharmaceuticals LLC	2	$23
Radius Health, Inc.	1	$21
Acerus Pharmaceuticals Corporation	1	$20
Rochester Medical Corporation	1	$20
Alfasigma USA, Inc.	1	$20
Ultragenyx Pharmaceutical Inc.	1	$19
Chiesi USA, Inc.	1	$19
Embecta Corp.	1	$18
GSK	1	$17
Aegerion Pharmaceuticals, Inc.	1	$17
Tolmar, Inc.	1	$17
Currax Pharmaceuticals LLC	1	$15
Regeneron Healthcare Solutions, Inc.	1	$15
Kowa Pharmaceuticals America, Inc.	1	$11

How this compares

$15,596 in reported general payments places this provider in the 65th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi →

Medicare billing

Part B allowed, 2024

$313,190

Medicare patients

818

Services billed

11,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jackson

Honey EastJackson$904K
Eric DyessJackson$885K
Ben SealeJackson$623K
Amanda SchieferJackson$204K
John SistrunkJackson$133K
Vishnu GarlaJackson$88K
Vanessa SandiferJackson$14K
John KnightJackson$9K
Jana PhillipsJackson$8K
Robert EvansJackson$8K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →